Cover Image
市場調查報告書

Immunomic Therapeutics, Inc.的產品平台分析

Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 259352
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Immunomic Therapeutics, Inc.的產品平台分析 Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016
出版日期: 2016年02月29日 內容資訊: 英文 42 Pages
簡介

Immunomic Therapeutics, Inc.是總公司設立於美國的生物科技企業,利用以溶酶體膜糖蛋白為基礎的專利技術來開發疫苗。平台產品有針對過敏、癌症、傳染病等領域的免疫療法用醫藥品。

本報告提供Immunomic Therapeutics, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Immunomic Therapeutics, Inc. 的基本資料

  • Immunomic Therapeutics, Inc. 概要
  • 主要資訊
  • 企業資料

Immunomic Therapeutics, Inc. :R&D概要

  • 主要的治療範圍

Immunomic Therapeutics, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Immunomic Therapeutics, Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Immunomic Therapeutics, Inc. :藥物簡介

  • TriMix-DC Vaccine
  • Td+pp65 DC Vaccine
  • ASP-4070
  • Cell Therapy for HIV
  • EGFRvIII DC Vaccine
  • HIV-LAMP-Vax
  • MC-LAMP-Vax
  • ARA-LAMP-Vax
  • JCC-LAMP-Vax
  • LAMP + Antigen mRNA Vaccine
  • Multi-LAMP-Vax

Immunomic Therapeutics, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Immunomic Therapeutics, Inc. :最新的開發平台資訊

Immunomic Therapeutics, Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07971CDB

Summary

Global Markets Direct's, 'Immunomic Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Immunomic Therapeutics, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immunomic Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Immunomic Therapeutics, Inc.
  • The report provides overview of Immunomic Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Immunomic Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Immunomic Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Immunomic Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Immunomic Therapeutics, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Immunomic Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Immunomic Therapeutics, Inc. Snapshot
    • Immunomic Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Immunomic Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Immunomic Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Immunomic Therapeutics, Inc. - Pipeline Products Glance
    • Immunomic Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Immunomic Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Immunomic Therapeutics, Inc. - Drug Profiles
    • TriMix-DC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-4070
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for HIV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target EGFRvIII for Glioblastoma Multiforme
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MC-LAMP-Vax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pp65 DC + Td
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARA-LAMP-Vax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HIV-LAMP-Vax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TN-LAMP-vax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antigen mRNA Vaccine + LAMP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JCC-LAMP-Vax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Multi-LAMP-Vax
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Immunomic Therapeutics, Inc. - Pipeline Analysis
    • Immunomic Therapeutics, Inc. - Pipeline Products by Target
    • Immunomic Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Immunomic Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Immunomic Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Immunomic Therapeutics, Inc. - Recent Pipeline Updates
  • Immunomic Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immunomic Therapeutics, Inc., Key Information
  • Immunomic Therapeutics, Inc., Key Facts
  • Immunomic Therapeutics, Inc. - Pipeline by Indication, 2016
  • Immunomic Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Immunomic Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Immunomic Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Immunomic Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2016
  • Immunomic Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Immunomic Therapeutics, Inc. - Phase II, 2016
  • Immunomic Therapeutics, Inc. - Phase I, 2016
  • Immunomic Therapeutics, Inc. - Preclinical, 2016
  • Immunomic Therapeutics, Inc. - Discovery, 2016
  • Immunomic Therapeutics, Inc. - Pipeline by Target, 2016
  • Immunomic Therapeutics, Inc. - Pipeline by Route of Administration, 2016
  • Immunomic Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • Immunomic Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Immunomic Therapeutics, Inc. - Recent Pipeline Updates, 2016
  • Immunomic Therapeutics, Inc., Other Locations

List of Figures

  • Immunomic Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016
  • Immunomic Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Immunomic Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Immunomic Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Immunomic Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2016
  • Immunomic Therapeutics, Inc. - Pipeline by Top 10 Target, 2016
  • Immunomic Therapeutics, Inc. - Pipeline by Route of Administration, 2016
  • Immunomic Therapeutics, Inc. - Pipeline by Molecule Type, 2016
Back to Top